News // Letter From Our President

Letter From Our President

Dear Valued Customers & Partners,

In 2021 we will celebrate 10 years as an Analytical Chemistry and Microbiology “think tank.” I founded Emery Pharma in September 2011 while still the CEO of NovaBay Pharmaceuticals. Our express purpose was to use our expertise to help NovaBay and the myriad Biotechs of all sizes sprouting up around the San Francisco bay area and beyond. From the very beginning, we chose to only accept research projects that helped save lives and or supported environmental sustainability. We intentionally rejected projects that we deemed detrimental to the health and well-being of both people and the environment such as a better e-cigarette, technologies polluting our environment, etc.

The year 2020 has placed the importance of SCIENCE at the forefront of a national discussion around, how we as a country, should respond to the novel Coronavirus. While individuals and institutions have taken side on a political divide, the importance of following scientific principles have never been debated at Emery Pharma. Emery has grown significantly since those early days and our commitment to our founding ideals have become stronger and more resolute as we dealt with the challenges of 2020.

We started the year on a high note by filing the key Citizen Petition that resulted in the FDA ordering a nationwide recall for Zantac® (Ranitidine). Our discovery pointed to carcinogenic impurities that could grow as a function of time and exposure to higher temperatures. We are now actively monitoring a number of medications for such potential impurity, solely at our own expense. We further plan to take appropriate action as we find any drug safety issues. As the year continued, in March of 2020, with the pandemic in full swing and “shelter in place” the new norm, the Emery Pharma team was on the front lines. We pivoted our microbiology team to develop a platform assay from ground up to screen novel antivirals against a Coronavirus surrogate (OC43), which has been extremely rewarding as several programs have made their way through Emergency Use Authorization (EUA).

In 2020 the entire world has come to realize the only way to return to normal is to trust science and scientists. Hopefully, the year has also taught us how to be a good steward of planet Earth, how to protect our own environment, as well as all living beings. True to our mission statement, we continue to support companies developing drugs or vaccines to help save lives, more efficient battery technologies, or ways to better recycle plastic. I could not be prouder of my co-workers at Emery Pharma for their insatiable curiosity and commitment to our core values.

As 2021 approaches, we can agree that sustainability of our environment and safe-guarding human health must continue to be our number one priority. At Emery Pharma we will hold these values at the highest level. From the bottom of my heart I want to thank the entire Emery Pharma team, our supporters, clients, and partners for allowing us to serve and make an impact. We look forward to continuing our mission and our journey to pave the path into a successful 2021!

Happy Holidays,

Ron Najafi, Ph.D.
President & Chief Executive Officer

Emery Pharma

Emery Pharma is a full-service contract research laboratory, specializing in analytical, bioanalytical chemistry, microbiology & cell biology services, custom synthesis, and general R&D and cGMP/GLP support.